Robert M Tulloh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3918633/publications.pdf

Version: 2024-02-01

110 papers	3,062 citations	172457 29 h-index	182427 51 g-index
115 all docs	115 docs citations	115 times ranked	3950 citing authors

#	Article	IF	Citations
1	Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom. Journal of the American Heart Association, 2022, 11, e023035.	3.7	8
2	Corticosteroids for the treatment of Kawasaki disease in children. The Cochrane Library, 2022, 2022, .	2.8	11
3	A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. The Lancet Child and Adolescent Health, 2021, 5, 133-141.	5.6	228
4	Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion. ESC Heart Failure, 2021, 8, 1901-1914.	3.1	9
5	Does Maintenance of Pulmonary Blood Flow Pulsatility at the Time of the Fontan Operation Improve Hemodynamic Outcome in Functionally Univentricular Hearts?. Pediatric Cardiology, 2021, 42, 1180-1189.	1.3	2
6	Pulmonary arterial hypertension in adults with congenital heart disease: markers of disease severity, management of advanced heart failure and transplantation. Expert Review of Cardiovascular Therapy, 2021, 19, 837-855.	1.5	2
7	Inflammatory markers in Eisenmenger syndrome and their association with clinical outcomes. A cross-sectional comparative study. International Journal of Cardiology, 2021, 342, 34-38.	1.7	2
8	Can we avoid the complications of the Fontan operation in those with suboptimal anatomy?. International Journal of Cardiology, 2020, 302, 43-44.	1.7	1
9	Outcomes following aortic valve procedures in 201 complex congenital heart disease casesâ€"results from the UK National Audit. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 547-554.	1.1	2
10	Intermittent antegrade warm-blood versus cold-blood cardioplegia in children undergoing open heart surgery: a protocol for a randomised controlled study (Thermic-3). BMJ Open, 2020, 10, e036974.	1.9	4
11	Should we use steroids as primary therapy for Kawasaki disease?. Archives of Disease in Childhood, 2020, 105, 1120.1-1124.	1.9	4
12	NF-ÎºB inhibition prevents acute shear stress-induced inflammation in the saphenous vein graft endothelium. Scientific Reports, 2020, 10, 15133.	3.3	24
13	Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. Journal of Pediatrics, 2020, 222, 261-262.	1.8	83
14	Age over 35 years is associated with increased mortality after pulmonary valve replacement in repaired tetralogy of Fallot: results from the UK National Congenital Heart Disease Audit database. European Journal of Cardio-thoracic Surgery, 2020, 58, 825-831.	1.4	6
15	Reply. Journal of Pediatrics, 2020, 224, 184-185.e1.	1.8	7
16	Cortisol/cortisone levels and quality of life in individuals with pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-4.	1.7	1
17	Lifetime cardiovascular management of patients with previous Kawasaki disease. Heart, 2020, 106, 411-420.	2.9	54
18	Advanced therapies in complex congenital heart disease. Journal of Congenital Cardiology, 2020, 4, .	0.5	1

#	Article	IF	Citations
19	Identification of atrial fibrillation in secondary care diabetes and vascular clinics: a pilot study. Future Cardiology, 2020, 16, 179-188.	1.2	0
20	Strategies for the management of pulmonary arterial hypertension in patients with congenital heart disease. Journal of Congenital Cardiology, 2020, 4, .	0.5	5
21	Advanced therapies in pulmonary arterial hypertension and congenital heart disease in people with Down syndrome. Journal of Congenital Cardiology, 2020, 4, .	0.5	1
22	Fifteen-minute consultation: Kawasaki disease: how to distinguish from other febrile illnesses: tricks and tips. Archives of Disease in Childhood: Education and Practice Edition, 2020, 105, 152-156.	0.5	0
23	Kawasaki disease: a prospective population survey in the UK and Ireland from 2013 to 2015. Archives of Disease in Childhood, 2019, 104, 640-646.	1.9	79
24	2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. Journal of Heart and Lung Transplantation, 2019, 38, 879-901.	0.6	266
25	Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. Cardiology in the Young, 2019, 29, 1323-1327.	0.8	5
26	Surgical versus balloon valvotomy in neonates and infants: results from the UK National Audit. Open Heart, 2019, 6, e000938.	2.3	6
27	Surgical Repair of Tetralogy of Fallot With Absent Pulmonary Valve: Favorable Long-Term Results. Seminars in Thoracic and Cardiovascular Surgery, 2019, 31, 847-849.	0.6	9
28	Assessment of Myocardial Function in Kenyan Children With Severe, Acute Malnutrition. JAMA Network Open, 2019, 2, e191054.	5.9	18
29	Congenital heart disease, pulmonary arterial hypertension and the UKâ€™s Drivers and Vehicle Licensing Agency: controversial new guidance. Pulmonary Circulation, 2019, 9, 1-2.	1.7	0
30	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1800332.	6.7	110
31	The cardiac proteome in patients with congenital ventricular septal defect: A comparative study between right atria and right ventricles. Journal of Proteomics, 2019, 191, 107-113.	2.4	7
32	Lung Function, Inflammation, and Endothelinâ€1 in Congenital Heart Diseaseâ€“Associated Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2018, 7, .	3.7	17
33	Changes in contractile protein expression are linked to ventricular stiffness in infants with pulmonary hypertension or right ventricular hypertrophy due to congenital heart disease. Open Heart, 2018, 5, e000716.	2.3	15
34	Primary repair versus surgical and transcatheter palliation in infants with tetralogy of Fallot. Heart, 2018, 104, 1864-1870.	2.9	19
35	Management of Adults With Congenital Heart Disease and Pulmonary Arterial Hypertension in the UK: Survey of Current Practice, Unmet Needs and Expert Commentary. Heart Lung and Circulation, 2018, 27, 1018-1027.	0.4	7
36	Giant coronary artery aneurysms in a 12-week-old infant with incomplete Kawasaki disease. BMJ Case Reports, 2018, 2018, bcr-2018-224479.	0.5	3

#	Article	IF	Citations
37	Echocardiographic Screening for Pulmonary Hypertension in CongenitalÂHeart Disease. Journal of the American College of Cardiology, 2018, 72, 2778-2788.	2.8	38
38	Cardiovascular adaptation to extra uterine life. Paediatrics and Child Health (United Kingdom), 2018, 28, 549-555.	0.4	0
39	Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease. Pulmonary Circulation, 2018, 8, 1-12.	1.7	15
40	A pilot randomised controlled trial investigating a mindfulness-based stress reduction (MBSR) intervention in individuals with pulmonary arterial hypertension (PAH): the PATHWAYS study. Pilot and Feasibility Studies, 2018, 4, 78.	1.2	14
41	Respiratory virus prophylaxis in congenital heart disease. Future Cardiology, 2018, 14, 417-425.	1.2	7
42	Pulmonary hypertension in congenital heart disease. Future Cardiology, 2018, 14, 343-353.	1.2	53
43	Inherited Pulmonary Arterial Hypertension. , 2018, , 741-753.		0
44	Corticosteroids for the treatment of Kawasaki disease in children. The Cochrane Library, 2017, 2017, CD011188.	2.8	68
45	Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease. Heart Lung and Circulation, 2017, 26, 1113-1116.	0.4	24
46	CHD and respiratory syncytial virus: global expert exchange recommendations. Cardiology in the Young, 2017, 27, 1504-1521.	0.8	19
47	Pulse oximetry screening for critical congenital heart defects: a European consensus statement. The Lancet Child and Adolescent Health, 2017, 1, 88-90.	5.6	34
48	Kawasaki disease and coronary artery aneurysms: from childhood to adulthood. Future Cardiology, 2017, 13, 491-501.	1.2	5
49	Retrospective study of the impact of unrecognised Kawasaki disease, coronary aneurysm and ectasia. International Journal of Cardiology, 2017, 248, 308-313.	1.7	9
50	Paediatric pulmonary hypertension: aetiology, pathophysiology and treatment. Paediatrics and Child Health (United Kingdom), 2017, 27, 50-57.	0.4	1
51	Sildenafil in Infants and Children. Children, 2017, 4, 60.	1.5	14
52	The Perception of a Three-Dimensional-Printed Heart Model from the Perspective of Different Stakeholders: A Complex Case of Truncus Arteriosus. Frontiers in Pediatrics, 2017, 5, 209.	1.9	29
53	Kawasaki disease incidence in children and adolescents: an observational study in primary care. British Journal of General Practice, 2016, 66, e271-e276.	1.4	28
54	Sildenafil, pulmonary hypertension and bronchopulmonary dysplasia. Early Human Development, 2016, 102, 21-24.	1.8	9

#	Article	IF	Citations
55	The incidence of Kawasaki disease after vaccination within the UK preâ€school National Immunisation Programme: an observational THIN database study. Pharmacoepidemiology and Drug Safety, 2016, 25, 1331-1336.	1.9	7
56	Cellular and molecular basis of RV hypertrophy in congenital heart disease. Heart, 2016, 102, 12-17.	2.9	33
57	Does the persistence of pulsatile antegrade pulmonary blood flow following bidirectional Glenn procedure affect long term outcome?â€. European Journal of Cardio-thoracic Surgery, 2015, 47, 154-158.	1.4	25
58	Pulmonary arterial hypertension exacerbated by ruxolitinib. Haematologica, 2015, 100, e244-e245.	3.5	37
59	Fifteen-minute consultation: rheumatic fever. Archives of Disease in Childhood: Education and Practice Edition, 2015, 100, 176-179.	0.5	1
60	Sildenafil in bronchopulmonary dysplasia: safe to use?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2015, 100, F369.2-F369.	2.8	7
61	Comparison of the effect of inhaled anaesthetic with intravenous anaesthetic on pulmonary vascular resistance measurement during cardiac catheterisation. Cardiology in the Young, 2015, 25, 368-372.	0.8	2
62	Anomalous Left Coronary From the Pulmonary Artery Presenting as Ventricular Fibrillation After Persistent Ductus Arteriosus Ligation. Annals of Thoracic Surgery, 2015, 100, e9-e10.	1.3	7
63	Cardiac problems in Down syndrome. Paediatrics and Child Health (United Kingdom), 2015, 25, 23-29.	0.4	16
64	Authors' response to â€˜Aspirin dose for treatment of Kawasaki diseaseâ€™. Archives of Disease in Childhood, 2015, 100, 300.2-301.	1.9	2
65	Patent ductus arteriosus: an analysis of management. Cardiology in the Young, 2014, 24, 941-943.	0.8	1
66	Use of phase-contrast magnetic resonance angiography to measure adaptations of aortic and pulmonary artery flow during supine aerobic exercise. Lancet, The, 2014, 383, S80.	13.7	0
67	Adaptations of aortic and pulmonary artery flow parameters measured by phase-contrast magnetic resonance angiography during supine aerobic exercise. European Journal of Applied Physiology, 2014, 114, 1013-1023.	2.5	12
68	Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective. Future Cardiology, 2014, 10, 235-242.	1.2	5
69	Kawasaki disease. BMJ, The, 2014, 349, g5336-g5336.	6.0	16
70	Evolving Management of Pediatric Pulmonary Arterial Hypertension: Impact of Phosphodiesterase Inhibitors. Pediatric Cardiology, 2013, 34, 213-219.	1.3	11
71	High haematocrit in cyanotic congenital heart disease affects how fibrinogen activity is determined by rotational thromboelastometry. Thrombosis Research, 2013, 132, e145-e151.	1.7	23
72	Paediatric pulmonary hypertension and sildenafil: current practice and controversies. Archives of Disease in Childhood: Education and Practice Edition, 2013, 98, 141-147.	0.5	27

#	Article	IF	Citations
73	The utility of sildenafil in pulmonary hypertension: a focus on bronchopulmonary dysplasia. Archives of Disease in Childhood, 2013, 98, 613-617.	1.9	53
74	Atrial septal defect closure with an Amplatzer septal occluder fenestrated with a coronary stent in a child with pulmonary arterial hypertension. Cardiology in the Young, 2013, 23, 692-696.	0.8	10
75	Being mindful of pulmonary arterial hypertension. British Journal of Cardiac Nursing, 2013, 8, 127-133.	0.1	0
76	The sinister course of an intramural right coronary artery. Cardiology in the Young, 2012, 22, 206-208.	0.8	0
77	Update on pulmonary arterial hypertension in children: management strategies and clinical utility of sildenafil. Pediatric Health, Medicine and Therapeutics, 2012, , 59.	1.6	0
78	Cardiac problems in Down syndrome. Paediatrics and Child Health (United Kingdom), 2011, 21, 25-31.	0.4	3
79	Management of pulmonary hypertension in Down syndrome. European Journal of Pediatrics, 2011, 170, 915-921.	2.7	50
80	A Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically Significant Congenital Heart Disease. Pediatric Research, 2011, 70, 186-191.	2.3	87
81	Cardiac function and hemodynamics in Kenyan children with severe malaria. Critical Care Medicine, 2010, 38, 940-945.	0.9	68
82	Treatment of pediatric pulmonary hypertension. Vascular Health and Risk Management, 2009, 5, 509.	2.3	19
83	Kawasaki disease in children. Heart, 2009, 95, 787-792.	2.9	70
84	Etiology, Diagnosis, and Pharmacologic Treatment of Pediatric Pulmonary Hypertension. Paediatric Drugs, 2009, 11, 115-128.	3.1	19
85	Takayasuâ€™s disease: a review. Cardiology in the Young, 2008, 18, 250-259.	0.8	61
86	Eisenmengerâ€™s syndrome:A review of the pathophysiology and therapeutic options. British Journal of Cardiac Nursing, 2008, 3, 138-145.	0.1	10
87	Kawasaki disease: diagnosis, management and cardiac sequelae. Expert Review of Cardiovascular Therapy, 2007, 5, 553-561.	1.5	9
88	Management and therapeutic options in pediatric pulmonary hypertension. Expert Review of Cardiovascular Therapy, 2006, 4, 361-374.	1.5	11
89	The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease. Cardiology in the Young, 2005, 15, 274-278.	0.8	19
90	Measurement of total pulmonary arterial compliance using invasive pressure monitoring and MR flow quantification during MR-guided cardiac catheterization. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H1301-H1306.	3.2	77

#	Article	IF	Citations
91	Transforming Growth Factor-Î² Receptor Mutations and Pulmonary Arterial Hypertension in Childhood. Circulation, 2005, 111, 435-441.	1.6	222
92	Intermediate-term outcome following the fontan operation: a survival, functional and risk-factor analysisâ˜†. European Journal of Cardio-thoracic Surgery, 2005, 28, 529-535.	1.4	61
93	Cardiac Magnetic Resonance Imaging After Stage I Norwood Operation for Hypoplastic Left Heart Syndrome. Circulation, 2005, 112, 3256-3263.	1.6	83
94	Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatric Respiratory Reviews, 2005, 6, 174-180.	1.8	32
95	Interventional cardiac catheterisation in congenital heart disease. Archives of Disease in Childhood, 2004, 89, 1168-1173.	1.9	23
96	Novel Method of Quantifying Pulmonary Vascular Resistance by Use of Simultaneous Invasive Pressure Monitoring and Phase-Contrast Magnetic Resonance Flow. Circulation, 2004, 110, 826-834.	1.6	156
97	An echocardiographic study of tetralogy of Fallot in the fetus and infant. Cardiology in the Young, 2003, 13, 240-247.	0.8	47
98	Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiology in the Young, 2003, 13, 420-423.	0.8	44
99	An echocardiographic study of tetralogy of Fallot in the fetus and infant. Cardiology in the Young, 2003, 13, 240-7.	0.8	9
100	Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiology in the Young, 2003, 13, 420-3.	0.8	8
101	Percutaneous retrieval of central venous catheter fragments. Archives of Disease in Childhood, 2002, 87, 149-150.	1.9	33
102	Coronary arterial complications before and after the arterial switch operation: is the future clear?. Cardiology in the Young, 2002, 12, 164-171.	0.8	7
103	Atrial Septal Defect with Failure to Thrive in Infancy: Hidden Pulmonary Vascular Disease?. Pediatric Cardiology, 2002, 23, 528-530.	1.3	45
104	Hypoplastic left heart syndrome: diagnosis and management. British Journal of Hospital Medicine, 2002, 63, 24-27.	0.2	4
105	Retrospective prenatal diagnosis of scimitar syndrome aided by three-dimensional power Doppler imaging. Ultrasound in Obstetrics and Gynecology, 2001, 17, 449-452.	1.7	25
106	Recurrent skin peeling following Kawasaki disease. Archives of Disease in Childhood, 2000, 83, 353-355.	1.9	29
107	Role of NO in recovery from neonatal hypoxic pulmonary hypertension. Thorax, 1999, 54, 796-804.	5.6	8
108	Cervical aortic arch with anomalous origin of the left subclavian artery from Kommerell's diverticulum. Cardiology in the Young, 1996, 6, 187-189.	0.8	1

#	Article	IF	Citations
109	Maturation of the Contractile Response and Its Endothelial Modulation in Newborn Porcine Intrapulmonary Arteries. Pediatric Research, 1995, 38, 25-29.	2.3	40
110	K (ATP) + Channels in Neonatal Pulmonary Vessels during Normal Development and Chronic Hypoxia. , 1994, , 213-224.		0